ChromaCode and MedGenome Announce Partnership to Bring HDPCR-Based Diagnostics to India and Middle East


Medical Device & Technology

ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East. With the size of the Indian genomics market estimated to reach $2.7 billion by 2023, there is an unmet need for advanced yet affordable molecular diagnostics solutions that can reach a broader population.

HDPCR™ technology is a revolutionary approach to the deep multiplexing of actionable biomarkers in a single, rapid, cost-effective assay for multiple sample types, with applications in oncology, minimal residual disease, transplant and noninvasive prenatal testing. This technology, deployed on ChromaCode’s cloud-based analysis platform, simplifies workflows, thus enabling laboratories worldwide to affordably conduct the testing internally and produce high quality, actionable results.

View full article

More Articles Here